MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Cardiovascular / Structural Heart / Cardiac Implants / Cardiac Dimensions touts Carillon TMVR study

Cardiac Dimensions touts Carillon TMVR study

September 12, 2019 By Sean Whooley Leave a Comment

Cardiac DimensionsCardiac Dimensions today touted a clinical study of its Carillon mitral contour system in treating the primary cause of functional mitral regurgitation (FRM) in patients with heart failure.

Carillon is a right heart transcatheter mitral valve repair (TMVR) device designed to treat FRM in patients with mitral regurgitation grades of 2+, 3+ and 4+ in heart failure.

The blinded, multi-center, randomized, sham-controlled clinical trial included 120 patients enrolled across 31 sites in Europe, Australia and New Zealand. Three out of four patients who were on heart failure medical therapy with FMR were treated with the Carillon system.

The study concluded that treatment with Carillon resulted in a statistically significant reduction of mitral regurgitant volume, as the Carillon group’s MR volume dropped 7.1 mL, compared to an increase of 3.3 mL in the control group. Left ventricular volumes also decreased in the Carillon group (-10.4 mL) while they increased in the control (+6.5 mL).

Patients treated with the Carillon device experienced 48% fewer heart failure hospitalizations during follow-up, according to the study.

The new study was published in the Journal of the American College of Cardiology: Heart Failure. In April, the Kirkland, Wash.-based company touted data from a previous study on the Carillon device, which has held CE Mark approval in Europe since 2011.

“We are pleased with the outcome of the Reduce FMR study and the significant benefit the Carillon system brings to patients,” Cardiac Dimensions president & CEO Gregory Casciaro said in a news release. “This study adds to the growing body of evidence demonstrating the effectiveness and safety of the Carillon system for FMR patients and underlines the value of treating earlier in the disease to slow the deterioration of heart failure. We are leveraging these positive clinical results, along with the German DRG reimbursement and expansion to other EU markets, to quicken the commercial adoption of the Carillon system.”

“We know that mitral regurgitation in the context of heart failure is strongly associated with increased morbidity and mortality,” added Dr. Horst Sievert, director and founder of the Cardiovascular Center, Frankfurt. “Carillon provides an option to treat a large portion of FMR patients with a minimally invasive treatment that doesn’t compromise the valve leaflets. Patients across a wide spectrum of MR grade and (heart failure) class benefited from Carillon treatment, experiencing significant improvements in MR and favorable remodeling of the left ventricle. Heart failure is a progressive disease and we need options that allow for progressive treatment.”

Filed Under: Cardiac Implants, Cardiovascular, Catheters, Clinical Trials, Featured, News Well Tagged With: Cardiac Dimensions Inc.

In case you missed it

  • Edwards projects $5 billion in sales for 2020
  • SPR Therapeutics announces 1000th placement of nerve stimulation device
  • The best places to work for medtech sales reps
  • DePuy Synthes issues urgent field safety notice for USS II Polyaxial 3D heads
  • Haemonetics (HAE) launches SafeTrace Tx in North America
  • Vicarious Surgical wins FDA breakthrough designation for surgical robot
  • Natus Medical issues field safety notice for snap electrode leads
  • J&J’s Ethicon gets to substitute 20 new claims on surgical stapler patent
  • Minerva Surgical raises $10m
  • Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
  • Orthofix names new president of global spine business
  • J&J Vision launches Tecnis Toric II intraocular lens in U.S.
  • NOUS Imaging picks up $6.6m for brain-imaging software
  • MicroVention issues safety notice for Azur endovascular embolization products
  • New study touts positive long-term results for Boston Sci’s Watchman
  • 3M issues safety notice for Durapore Advanced surgical tape
  • FDA clearance positions Sight Diagnostics to deliver on two-drop blood testing promise

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS